866758-52-3Relevant academic research and scientific papers
Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2
Duncton, Matthew A.J.,Piatnitski Chekler, Eugene L.,Katoch-Rouse, Reeti,Sherman, Dan,Wong, Wai C.,Smith II, Leon M.,Kawakami, Joel K.,Kiselyov, Alexander S.,Milligan, Daniel L.,Balagtas, Chris,Hadari, Yaron R.,Wang, Ying,Patel, Sheetal N.,Rolster, Robin L.,Tonra, James R.,Surguladze, David,Mitelman, Stan,Kussie, Paul,Bohlen, Peter,Doody, Jacqueline F.
experimental part, p. 731 - 740 (2009/07/25)
A series of arylphthalazine derivatives were synthesized and evaluated as antagonists of VEGF receptor II (VEGFR-2). IM-094482 57, which was prepared in two steps from commercially available starting materials, was found to be a potent inhibitor of VEGFR-
Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II
Duncton, Matthew A. J.,Piatnitski, Evgueni L.,Katoch-Rouse, Reeti,Smith II, Leon M.,Kiselyov, Alexander S.,Milligan, Daniel L.,Balagtas, Chris,Wong, Wai C.,Kawakami, Joel,Doody, Jacqueline F.
, p. 1579 - 1581 (2007/10/03)
A novel class of 1-(isoquinolin-5-yl)-4-arylamino-phthalazines is described as inhibitors of vascular endothelial growth factor receptor II (VEGFR-2). Many compounds display VEGFR-2 inhibitory activity with an IC50 as low as 0.017 μM in an HTRF
Arylphthalazines: Identification of a new phthalazine chemotype as inhibitors of VEGFR kinase
Piatnitski, Evgueni L.,Duncton, Matthew A. J.,Kiselyov, Alexander S.,Katoch-Rouse, Reeti,Sherman, Dan,Milligan, Daniel L.,Balagtas, Chris,Wong, Wai C.,Kawakami, Joel,Doody, Jacqueline F.
, p. 4696 - 4698 (2007/10/03)
A novel class of 4-arylamino-phthalazin-1-yl-benzamides is described as inhibitors of vascular endothelial growth factor receptor II (VEGFR-2). Several compounds display potent VEGFR-2 inhibitory activity with an IC50 as low as 0.078 μM in an H
